Generic Drugs Market

Generic Drugs Market GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK,
AND OPPORTUNITY ANALYSIS, 2018-2026
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Generic Drugs Market – Overview
Generic drugs market growth is buoyed by increasing number of patented expiries for drugs each year. According to
the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as
U.S and Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are
expected to lose patent protection over the next three years i.e from 2017 and 2020, which is expected to drive
growth of the generic drugs market.
Global generics market is highly competitive with many Asia Pacific companies entering the developed markets
such as the U.S., Germany, France, and UK. Recent past has witnessed spurt in mergers and acquisitions between
generic drug manufacturers, with major players focusing on enhancing their product portfolio through such inorganic
strategies. For instance, Teva Pharmaceutical Industries Pvt. Ltd., Pfizer, Inc., Mylan, Sun Pharmaceutical, and
Fresenius Kabi entered into acquisitions to increase their revenue share in the generic drugs market.
Increase in number of competitor’s for generic drugs market put the pressure on manufacturers of pricing. Moreover,
price celling actions by respective governments is further aggravating the profit margins of generic drug
manufacturers. Considering the challenges of pricing pressure as generics outfits feel the pinch with thin margins,
the market is expected to exhibit steady growth in the future.
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Competitive Analysis:
●
●
●
Teva Pharmaceuticals Industries strengthened its position in the generic drugs market through acquisition
of the generic segment of Allergan, plc for US$ 40.5 billion in August 2016. This resulted in significant
growth in revenue contribution of its generic drug segment, pegged at US$ 9.5 billion in 2016.
Mylan ranks second in the list of generic drug manufacturers, and this is due to the acquisition valued at
US$ 7.2 Bn of Sweden’s Meda by Mylan, in year 2016. This also aided Mylan to increase its sales of overthe-counter drugs and expand its presence in new emerging markets such as China, Southeast Asia, Russia,
and the Middle East.
Sandoz—Novartis Group’s business segment dealing in generic medicines—reported rampant growth of 9%
Y-o-Y in 2016, in sales volume, with revenue pegged at US$ 9 Bn. However, it was partially offset by a 6%
erosion in price. Pfizer is at the fourth position (US$ 4.6 Bn revenue in 2016). Pfizer acquired Hospira in
2015, in order to increase its product portfolio of both generic and branded products. Pfizer offers over 220
injectable medications, plus other off-brand products, which is expected to aid in gaining high revenue in
near future. Patent loss of Viagra in 2017, will lead to significant generic competition from Teva and Mylan.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1084
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Generic Drugs Market: Key Players
●
TEVA PHARMACEUTICAL INDUSTRIES
●
MYLAN N.V.
●
NOVARTIS INTERNATIONAL AG.
●
PFIZER, INC..
●
ALLERGAN PLC.
●
SUN PHARMACEUTICALS.
●
FRESENIUS KABI.
●
ENDO INTERNATIONAL.
●
LUPIN LIMITED
●
SANOFI
View this report @ https://www.coherentmarketinsights.com/ongoing-insight/generic-drugs-market-global-competitive-analysis-1084
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization
focused on assisting its plethora of clients achieve transformational growth by helping
them make critical business decisions. We are headquartered in India, with an office at
the global financial capital in the U.S. Our client base includes players from across all
business verticals in over 150 countries worldwide. We are uniquely positioned to help
businesses around the globe deliver practical and lasting results through various
recommendations about operational improvements, technologies, emerging market
trends and new working methods. We offer both customized and syndicated market
research reports that help our clients create visionary growth plans to provide traction to
their business. We meticulously study emerging trends across various industries at both
the global and regional levels to identify new opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
SECTOR COVERAGE
Healthcare
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL IMAGING
PHARMACEUTICAL
MEDICAL DEVICES
Chemicals & Materials
Bulk Chemicals
Advanced
Materials
Speciality and Fine Chemicals
Green Chemicals
Food Ingredients
© Coherent market Insights. All Rights Reserved
Cosmetic Ingredients
Polymers & Resins
ABOUT COHERENT MARKET INSIGHTS
KEY STATS
RESEARCH SOLUTIONS
FEASIBILITY
STUDIES
GLOBAL
REPORTS
100+
Insights Published Per Year
150+
Consulting Projects Till Date
125+
Clients Worldwide Per Year
110+
COUNTRY
ANALYSIS
CONSULT
PROJECTS
SURVEY
RESEARC
H
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and
food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across
various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our
clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained
growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein.
© Coherent market Insights. All Rights Reserved
To k no w mor e abo ut us , v is it o ur w eb site:
w ww.coh er en tmark etins ig hts.com
THANK YOU
© Coherent market Insights. All Rights Reserved
F or s ales q ueries o r new top ics email u s o n :
s ales@coh er en tmark etins ig hts .co m
Fo r o th er q uer ies co n tact:
Mr. Sh ah
( Man ag er - Bus iness D ev elo pment)
Co herent Mark et Ins ig hts
s ales@coh er en tmark etins ig hts .co m
+1 -2 06 -7 0 1- 67 02

Generic drugs market growth is buoyed by increasing number of patented expiries for drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S and Europe between 2014 and 2018.

Download Report